Copyright
©2010 Baishideng. All rights reserved.
World J Diabetes. Mar 15, 2010; 1(1): 19-26
Published online Mar 15, 2010. doi: 10.4239/wjd.v1.i1.19
Published online Mar 15, 2010. doi: 10.4239/wjd.v1.i1.19
Effect of vildagliptin as add-on therapy to a low-dose metformin
Claudia Filozof, Diabetes Principal Medical Scientific Expert, Novartis Pharma AG, Fabrikstrasse 4-4.43.4, CH-4056 Basel, Switzerland
Sherwyn Schwartz, Diabetes and Glandular Disease Clinic, San Antonio, TX 78229, United States
James E Foley, Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, United States
Author contributions: Filozof C and Foley JE wrote this paper on behalf of many individuals at Novartis who contributed to the design, implementation, analysis and reporting of the data including Valentin M, Colin L, Holmes D, Thuren T, Buccheit F, Degen J and Kothny W; Schwartz S wrote this paper as the principal investigator on behalf of the study investigators; Filozof C and Foley J are employees of Novartis Pharmaceuticals Corporation and hold stocks in the company; Schwartz S was involved in the conduct of the study as a clinical trial investigator. No additional known conflict of interest exists and no honoraria were offered or received for coauthor participation in the writing of this manuscript.
Supported by Novartis Pharmaceuticals Corporation, NCT00396357
Correspondence to: Claudia Filozof, MD, PhD, Diabetes Principal Medical Scientific Expert, Novartis Pharma AG, Fabrikstrasse 4-4.43.4, CH-4056 Basel, Switzerland. claudia.filozof@novartis.com
Telephone: +41-61-3242987 Fax: +41-61-3247921
Received: October 9, 2009
Revised: January 7, 2010
Accepted: January 14, 2010
Published online: March 15, 2010
Revised: January 7, 2010
Accepted: January 14, 2010
Published online: March 15, 2010
Core Tip